Sirtuin 1 activator SRT2104 protects Huntington's disease mice

Authors:

Abstract
Sirtuin 1 is a nicotinamide adenine dinucleotide‐dependent protein deacetylase which regulates longevity and improves metabolism. Activation of Sirtuin 1 confers beneficial effects in models of neurodegenerative diseases. We and others have provided convincing evidence that overexpression of Sirtuin 1 plays a neuroprotective role in mouse models of Huntington's disease. In this study, we report that SRT2104, a small molecule Sirtuin 1 activator, penetrated the blood–brain barrier, attenuated brain atrophy, improved motor function, and extended survival in a mouse model of Huntington's disease. These findings imply a novel therapeutic strategy for Huntington's disease by targeting Sirtuin 1.
Funding Information
  • National Institutes of Health (NS082338)
  • Cure Huntington's Disease Initiative (A3875)
  • Sirtris, A GSK company (A39636)

This publication has 19 references indexed in Scilit: